Argenica Therapeutics Ltd has released a press release.
Argenica Therapeutics: Half Yearly Report and Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- Successful Applicaton for EMA Paediatric Waiver
- Quarterly Activities/Appendix 4C Cash Flow Report
- AI Analysis Reveals Efficacy In Severe Stroke Patients
- Positive TNK Study Results Fulfil Key FDA Requirement
- ARG-007 Efficacious Dose Validated in New Preclinical Study
Later from Argenica Therapeutics
- Argenica Receives $3.97m R&D Tax Incentive Cash Rebate
- Presentations at European Stroke Organisation Conference
- Clinical Advisory Committee Established to Advance Phase 2b
- IND Application Advanced With Successful Completion of Assay
- WHO Confirms Xaranetide as INN for ARG-007
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics